Ameriprise
IMVT icon

Ameriprise’s Immunovant IMVT Stock Holding History

Ameriprise’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,553
Closed -$377K – 4120
2025
Q2 		$377K Buy
+23,553
New +$356K ﹤0.01% 3621
2025
Q1 		– Sell
-8,907
Closed -$221K – 4089
2024
Q4 		$221K Buy
+8,907
New +$253K ﹤0.01% 3834
2024
Q3 		– Sell
-15,793
Closed -$417K – 3973
2024
Q2 		$417K Sell
15,793
-3,608
-19% -$103K ﹤0.01% 3477
2024
Q1 		$627K Buy
19,401
+5,751
+42% +$210K ﹤0.01% 3344
2023
Q4 		$575K Buy
13,650
+4,146
+44% +$153K ﹤0.01% 3403
2023
Q3 		$365K Sell
9,504
-1,990
-17% -$45K ﹤0.01% 3521
2023
Q2 		$218K Buy
11,494
+300
+3% +$5.59K ﹤0.01% 3709
2023
Q1 		$174K Sell
11,194
-1,625
-13% -$28.2K ﹤0.01% 3759
2022
Q4 		$228K Buy
+12,819
New +$161K ﹤0.01% 3674

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Ameriprise's IMVT Position: Q3 2025 in Review

Ameriprise sold out of Immunovant (IMVT) in Q3 2025, closing a stake of 23,553 shares — an estimated $377K sold.

Ameriprise first reported a position in IMVT in Q4 2022 and held it in 9 quarters. The position peaked at $627K in Q1 2024. 186 funds tracked by Wall St. Rank hold IMVT as of Q3 2025.

  • Ameriprise reported no remaining Immunovant position as of Q3 2025 after selling out during the quarter.
  • Ameriprise sold 23,553 Immunovant shares in Q3 2025, an estimated $377K.
  • Ameriprise first reported a position in Immunovant in Q4 2022 and held it in 9 quarters.
  • Ameriprise's Immunovant position peaked at $627K in Q1 2024.
  • 186 funds tracked by Wall St. Rank held Immunovant as of Q3 2025.

Based on Ameriprise's 13F filing for Q3 2025, filed 14 Nov 2025.